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Abstract
Background: Bilirubin has antioxidant properties against chronic respiratory diseases. However, previous studies are
limited by acquisition of serum bilirubin level at one time point and its analysis with clinical parameters. We
evaluated the association of serum bilirubin levels with various clinical outcomes of chronic obstructive pulmonary
disease (COPD) in Korean Obstructive Lung Disease (KOLD) cohort.
Methods: We included 535 patients with COPD from the KOLD cohort. Serum bilirubin levels and various clinical
parameters, such as lung function, 6-min walking (6 MW) distance, quality of life (QoL), and exacerbation, were
evaluated annually; their association was analyzed using generalized estimating equations and the linear mixed
model.
Results: Among 535 patients, 345 (64.5%) and 190 (35.5%) were categorized into Global Initiative for Chronic
Obstructive Lung Disease (GOLD) I-II and GOLD III-IV groups, respectively. 6 MW distance was positively associated
with serum bilirubin levels, especially in the GOLD I-II group (estimated mean = 41.5). Among QoL indexes, the
COPD assessment test score was negatively associated with serum bilirubin levels only in the GOLD I-II group
(estimated mean = − 2.8). Higher serum bilirubin levels were independently associated with a higher number of
acute exacerbation in the GOLD III-IV group (estimated mean = 0.45, P = 0.001). Multivariate analysis revealed that
lung function and mortality were not associated with serum bilirubin levels.
Conclusions: Higher serum bilirubin levels were associated with a longer 6 MW distance and better QoL, especially
in the GOLD I-II group, whereas they were related to a higher risk of acute exacerbation, especially in the GOLD III-
IV group. Bilirubin levels may represent various conditions in COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent respiratory symptoms and airflow
limitation caused by significant exposure to noxious par-
ticles or gases [1]. Oxidative stress is an important
mechanism in the development, progression, and exacer-
bation of COPD. Biomarkers of oxidative stress are ele-
vated in the exhaled breath, sputum, and blood of
patients with COPD [2].
Bilirubin is known as a potential antioxidant and pos-
sesses anti-inflammatory properties [3]. Elevated biliru-
bin levels have a protective effect in cardiovascular
disease and cardiovascular disease–related diseases [4].
Several reports demonstrate the relationship between
bilirubin level and respiratory diseases. In the United
Kingdom, higher level of bilirubin was associated with a
lower risk of COPD, lung cancer, and all-cause mortality
[5]. In the Swiss general population, serum bilirubin was
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positively associated with lung function [6]. In COPD,
bilirubin level was inversely related to COPD disease se-
verity and progression, and a higher bilirubin level was
associated with a lower risk for acute COPD exacerba-
tion, suggesting that bilirubin can be a biomarker of
COPD exacerbation [7, 8].
However, previous studies have a potential limitation
with respect to the acquisition of serum bilirubin level at
one time point and analyzing it with serial clinical pa-
rameters. Brown et al. analyzed the serum bilirubin level
through repeated measurements, but the interval of
measurement and total duration of the study were too
short to assess the relationship of serum bilirubin level
with various clinical outcomes in COPD [8]. For com-
parison with the results of previous conflict results, we
aimed to evaluate the association of both baseline and
repeatedly measured serum bilirubin levels with various
clinical outcomes of COPD in Korea, including lung




The study population initially consisted of 547 patients
from the KOLD cohort, in which patients with COPD or
asthma had been recruited from the pulmonary clinics
of 17 hospitals in South Korea between June 2005 and
December 2011 and are under continuous follow-up.
The inclusion criteria were a postbronchodilator ratio of
forced expiratory volume in 1 s to forced vital capacity
(FEV1/FVC) < 0.7, age > 40 years, smoking history ≥10
pack-years, and no or minimal abnormality on chest
radiography. Twelve patients were excluded (one had a
high bilirubin level, nine were hepatitis B virus carriers,
and two patients had moderate-to-severe liver diseases).
The severity of disease was based on the FEV1% pre-
dicted in accordance with previous Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria [1].
Bilirubin measurement
Venous blood samples were collected from the patients
at baseline and annually, unless they refused for any rea-
son. A high bilirubin level was defined as a bilirubin
concentration > 2.34 mg/dL for men and > 1.75 mg/dL
for women [9]. These limits represent concentrations 1
standard deviation (SD) above the mean serum total bili-
rubin related to the most common variant of Gilbert
syndrome, a benign hereditary cause of indirect hyperbi-
lirubinemia [5].
Clinical assessments
Clinical assessments include pulmonary function test re-
sults, 6-min walking (6MW) distance, QoL measured by
COPD Assessment Test (CAT) and St. George’s
Respiratory Questionnaire (SGRQ), exacerbations, and
mortality. These assessments were performed annually
on the same day as blood collection. The 6MW test was
conducted on a 20-m walking course [10]. Exacerbation
was defined as an unscheduled hospital visit or
hospitalization due to aggravation of one of three re-
spiratory symptoms, including cough, sputum, and dys-
pnea for 2 days or more.
Statistical analysis
We assessed the association between serum bilirubin
levels and clinical outcomes. First, to assess the baseline
bilirubin level that effects changes in lung function, 6
MW distance, CAT and SGRQ scores; and exacerbation
over time, we applied the linear mixed model and gener-
alized estimating equations (GEE) approach to the di-
chotomous and continuous outcomes, respectively for
regression analysis. Second, the marginal GEE approach
was implemented to account for the clustered measured
clinical outcomes and serum bilirubin levels in the same
patient for regression analysis. Age, sex, body mass index
(BMI), smoking status, and baseline FEV1 were included
in the model. We also examined the serum bilirubin
levels that affect mortality through the Cox regression
model using time-dependent repeated measurements.
Statistical analysis was conducted with SAS version 9.4
(SAS Institute, Inc., Cary, NC, USA). We performed uni-
variate analyses with the χ2 test for categorical variables
and Student’s t-test for continuous variables. A two-




The serum bilirubin levels did not vary between visits
over the follow-up period [see Additional file 1]. Table 1
shows the baseline characteristics of the whole study
group and the GOLD I-II/III-IV groups. Among the 535
patients, 345 (64.5%) and 190 (35.5%) were categorized
into GOLD I-II and GOLD III-IV groups, respectively.
The mean age was 67.9 years, 97% were male, 35.8%
were current smokers, the mean FEV1 was 1.72 L (56.8%
of predicted), the mean follow-up duration was 5.4 years,
and the mean bilirubin level was 0.68 ng/mL in the
whole group. BMI, lung function, and proportion of
current smokers were higher, and the 6MW distance
was longer in the GOLD I-II group than in the GOLD
III-IV group. QoL was better in the GOLD I-II group
than in the GOLD III-IV group according to CAT and
SGRQ scores. The number of exacerbations and the
mortality rate were higher in the GOLD III-IV group
than in the GOLD I-II group. Serum bilirubin level was
not different between the GOLD I-II and GOLD III-IV
groups.
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Pulmonary function
Table 2 shows the results of the regression analysis of
the relationship of serum bilirubin levels and pulmonary
function. Baseline serum bilirubin level was associated
with FEV1 (estimated mean = 0.19, P = 0.038) and FVC
(estimated mean = 0.34, P = 0.017) in the GOLD I-II
group according to the univariate analysis. However, the
multivariate analysis adjusted for age, sex, BMI, and
smoking status showed no significant association
between serum bilirubin levels and pulmonary function
in the analysis of the baseline level or in the clustered
analysis.
6MW distance and QoL
Table 3 shows the results of the regression analysis for
the association of serum bilirubin levels with 6MW dis-
tance and QoL index. In the whole group, the 6MW
distance (estimated mean = 31.0, P = 0.005) was
Table 1 Baseline characteristics of the KOLD study populationa
Parameters Whole Group (n = 535) GOLD I-II (n = 345) GOLD III-IV (n = 190) P-value†
Age, yr 67.9 ± 7.9 67.8 ± 8.4 67.9 ± 6.8 0.933
Sex, male 519 (97.0) 333 (96.5) 186 (97.9) 0.438
BMI, kg/m2 22.9 ± 3.0 23.5 ± 2.7 21.9 ± 3.3 < 0.001
Smoking
Current smokers 191 (35.8) 138 (40.0) 53 (28.0) 0.006
Former smokers 344 (64.2) 207 (60.0) 137 (72.0)
Lung function
FEV1, L 1.72 ± 0.59 2.02 ± 0.48 1.16 ± 0.28 < 0.001
FEV1, % predicted 56.8 ± 16.6 66.7 ± 10.9 38.9 ± 8.0 < 0.001
FVC, L 3.55 ± 0.79 3.78 ± 0.74 3.13 ± 0.70 < 0.001
FVC, % predicted 89.9 ± 17.1 94.6 ± 15.6 81.4 ± 16.5 < 0.001
FEV1/FVC, % 47.9 ± 11.2 53.4 ± 8.3 38.1 ± 8.8 < 0.001
GOLD classification
GOLD I 41 (7.7) 41 (11.9) 0 < 0.001
GOLD II 304 (56.8) 304 (88.1) 0
GOLD III 163 (30.5) 0 163 (85.8)
GOLD IV 27 (5.0) 0 27 (14.2)
Laboratory findings
White blood cell, /mm3
7282 ± 2058
7087 ± 1772 7627 ± 2346 0.006
Red blood cell, /mm3
4691 ± 444
4646 ± 445 4754 ± 441 0.012
Hemoglobin, g/dl
14.7 ± 1.3
14.6 ± 1.3 14.8 ± 1.3 0.071
AST, IU/L
24.0 ± 10.9
24.8 ± 12.5 22.8 ± 7.6 0.057
ALT, IU/L
21.7 ± 15
22.9 ± 17.7 20.2 ± 9.6 0.07
Baseline bilirubin level, ng/mL 0.68 ± 0.29 0.67 ± 0.29 0.69 ± 0.29 0.671
6 MW distance, m 413.1 ± 88.1 422.4 ± 81.2 399.4 ± 92.3 0.004
CAT score 12.0 ± 7.8 10.5 ± 7.0 15.8 ± 8.2 < 0.0001
SGRQ score 30.3 ± 18.4 25.1 ± 16.2 39.1 ± 18.5 < 0.0001
Exacerbation, yr 0.33 ± 0.68 0.22 ± 0.40 0.53 ± 0.97 < 0.0001
Follow-up duration, yr 5.4 ± 3.7 5.2 ± 3.6 5.9 ± 3.9 0.031
Mortality 58 (10.8) 23 (6.7) 35 (18.4) < 0.001
a Data are presented as numbers (percentages) or means ± standard deviation
† P-value for comparison between COPD patients with GOLD I-II and those with GOLD III-IV
BMI body mass index, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GOLD Global Initiative for Chronic Obstructive Lung Disease, AST aspartate
aminotransferase, ALT alanine aminotransferase, 6 MW 6-min walking, CAT COPD assessment test, SGRQ St. George’s Respiratory Questionnaire
Leem et al. Respiratory Research          (2019) 20:279 Page 3 of 8
positively associated with serum bilirubin level in the
multivariate clustered analysis. According to the sub-
group analysis, this positive association was observed
only in the GOLD I-II group (estimated mean = 41.5,
P = 0.002). Among the QoL index, SGRQ score was not
associated with serum bilirubin level in the analysis of
baseline level or in the clustered analysis. However, the
CAT score (estimated mean = − 1.9, P = 0.048) was nega-
tively associated with serum bilirubin level in the multi-
variate clustered analysis in the whole group. A negative
association between the serum bilirubin level and the
CAT score (estimated mean = − 2.8, P = 0.017) was ob-
served only in the GOLD I-II group when subgroup ana-
lysis was conducted.
Exacerbation
Table 4 shows the relationship between serum bilirubin
levels and the number of acute exacerbation per year. In
the whole group, a higher baseline serum bilirubin level
was independently associated with a higher risk of ex-
acerbation (estimated mean = 0.62, P = 0.001). According
to the subgroup analysis, this significant relationship was
observed only in the GOLD III-IV group. Number of
acute exacerbation per year was positively associated
with serum bilirubin both in the analysis of baseline bili-
rubin level (estimated mean = 0.75, P = 0.005) and in the
clustered analysis (estimated mean = 0.45, P = 0.001) in
the GOLD III-IV group (Table 4).
Mortality
Serum bilirubin level was not associated with mortality
in the whole group or in the subgroups in the analysis of
the baseline level or in the clustered analysis (Table 5).
Discussion
This study investigated the association of serum biliru-
bin levels with several clinical aspects, such as lung func-
tion, exercise capacity, QoL, exacerbation, and mortality,
through the Korean COPD cohort study. We found that
higher serum bilirubin level was associated with longer
6MW distance, better QoL, and higher risk of acute ex-
acerbation after adjusting for age, sex, BMI, smoking sta-
tus, and baseline FEV1. When stratifying patients
according to severity of airflow limitation, the
Table 2 Regression analysis for the relationship between serum bilirubin levels and pulmonary functiona
FEV1, L FVC, L FEV1/FVC, %
estimated mean (SE) P-value estimated mean (SE) P-value estimated mean (SE) P-value
Whole group
Univariate
Baseline bilirubin 0.08 (0.09) 0.382 0.18 (0.12) 0.121 − 0.52 (1.84) 0.776
Clustered analysis 0.05 (0.09) 0.585 0.13 (0.11) 0.255 − 0.33 (1.75) 0.85
Multivariateb
Baseline bilirubin 0.04 (0.08) 0.607 0.11 (0.11) 0.322 −0.45 (1.72) 0.792
Clustered analysis 0.02 (0.08) 0.798 0.05 (0.10) 0.662 0.08 (1.55) 0.959
GOLD I-II
Univariate
Baseline bilirubin 0.19 (0.09) 0.038 0.34 (0.14) 0.017 0.23 (1.76) 0.898
Clustered analysis 0.14 (0.09) 0.115 0.21 (0.14) 0.116 1.21 (1.52) 0.428
Multivariateb
Baseline bilirubin 0.11 (0.08) 0.169 0.19 (0.12) 0.111 −0.08 (1.69) 0.962
Clustered analysis 0.06 (0.07) 0.428 0.07 (0.12) 0.561 0.94 (1.36) 0.489
GOLD III-IV
Univariate
Baseline bilirubin −0.04 (0.09) 0.622 −0.02 (0.18) 0.925 −0.52 (2.39) 0.829
Clustered analysis −0.11 (0.08) 0.169 −0.02 (0.15) 0.916 −2.79 (2.55) 0.273
Multivariateb
Baseline bilirubin −0.07 (0.08) 0.349 −0.06 (0.17) 0.708 −0.91 (2.31) 0.694
Clustered analysis −0.12 (0.07) 0.103 −0.06 (0.14) 0.682 −2.59 (2.42) 0.285
a ‘baseline bilirubin’ is the results of regression analysis for clinical outcomes according to the baseline bilirubin levels. ‘Clustured analysis’ is the results of
regression analysis for clinical outcomes and repeated measured serum bilirubin levels
b adjusted with age, sex, body mass index, smoking (current and former) FEV1 forced expiratory volume in 1 s, SE standard error, FVC forced vital capacity, GOLD
Global Initiative for Chronic Obstructive Lung Disease
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association with better exercise capacity and better QoL
persisted only in the GOLD I-II group, whereas the asso-
ciation with a higher risk of exacerbation persisted only
in the GOLD III-IV group.
Bilirubin is a potential antioxidant against peroxyl rad-
icals and protects cells from toxic levels of hydrogen
peroxide [3]. Powerful antioxidant actions of bilirubin
arise from rapid regeneration to bilirubin via biliverdin
reductase after being oxidized back to biliverdin [11, 12].
Additionally, bilirubin attenuates vascular endothelial ac-
tivation and dysfunction in response to proinflammatory
stress [13].
These may explain how higher serum bilirubin levels
are associated with better exercise capacity in COPD.
Table 3 Regression analysis for the association of serum bilirubin levels with the 6-min walking distance and quality of life indexa
6 MW distance, m CAT SGRQ
estimated mean (SE) P-value estimated mean (SE) P-value estimated mean (SE) P-value
Whole group
Univariate
Baseline bilirubin 30.1 (14.3) 0.036 0.3 (1.3) 0.835 2.5 (2.9) 0.388
Clustered analysis 42.3 (12.5) 0.001 −2.40 (1.1) 0.028 −0.9 (2.6) 0.735
Multivariateb
Baseline bilirubin 20.5 (12.2) 0.094 0.4 (1.2) 0.746 2.9 (2.5) 0.261
Clustered analysis 31.0 (11.0) 0.005 −1.9 (0.9) 0.048 0.5 (2.2) 0.826
GOLD I-II
Univariate
Baseline bilirubin 38.6 (16.8) 0.023 −2.8 (1.5) 0.057 −2.2 (3.2) 0.498
Clustered analysis 52.4 (15.0) 0.001 −3.5 (1.2) 0.003 −3.1 (2.5) 0.218
Multivariateb
Baseline bilirubin 27.6 (14.8) 0.062 −2.1 (1.5) 0.154 −0.6 (3.2) 0.844
Clustered analysis 41.5 (13.3) 0.002 −2.8 (1.2) 0.017 −1.3 (2.6) 0.61
GOLD III-IV
Univariate
Baseline bilirubin 22.9 (25.4) 0.367 3.6 (2.2) 0.105 7.5 (4.6) 0.111
Clustered analysis 27.7 (19.8) 0.162 −0.7 (1.6) 0.666 2.3 (4.1) 0.569
Multivariateb
Baseline bilirubin 26.7 (20.4) 0.192 2.9 (1.9) 0.139 6.4 (4.2) 0.128
Clustered analysis 20.6 (16.8) 0.219 −0.3 (1.2) 0.818 2.1 (3.0) 0.49
a ‘baseline bilirubin’ is the results of regression analysis for clinical outcomes according to the baseline bilirubin levels. ‘Clustured analysis’ is the results of
regression analysis for clinical outcomes and repeated measured serum bilirubin levels
b Adjusted for age, sex, body mass index, smoking (current and former), and baseline forced expiratory volume in 1 s
6 MW 6-min walking, CAT COPD assessment test, SGRQ St. George’s Respiratory Questionnaire, SE standard error, GOLD Global Initiative for Chronic Obstructive
Lung Disease
Table 4 Regression analysis for the relationship between serum bilirubin levels and number of acute exacerbation per yeara
Whole Group GOLD I-II GOLD III-IV
Estimated mean (SE) P-value Estimated mean (SE) P-value Estimated mean (SE) P-value
Univariate
Baseline bilirubin 0.64 (0.19) 0.001 0.38 (0.23) 0.103 0.86 (0.27) 0.002
Clustered bilirubin 0.30 (0.21) 0.156 −0.15 (0.22) 0.502 0.62 (0.23) 0.008
Multivariateb
Baseline bilirubin 0.62 (0.18) 0.001 0.41 (0.24) 0.083 0.75 (0.27) 0.005
Clustered bilirubin 0.29 (0.15) 0.064 −0.08 (0.21) 0.704 0.45 (0.14) 0.001
a ‘baseline bilirubin’ is the results of regression analysis for clinical outcomes according to the baseline bilirubin levels. ‘Clustured analysis’ is the results of
regression analysis for clinical outcomes and repeated measured serum bilirubin levels
b adjusted with age, sex, body mass index, smoking (current and former), baseline FEV1 GOLD Global Initiative for Chronic Obstructive Lung Disease., SE
standard error
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This is the first study to demonstrate a positive associ-
ation between serum bilirubin level and 6MW distance
in COPD patients. However, the association was only
observed in the GOLD I-II group. In COPD patients
with severe airflow limitation, other factors such as BMI,
muscle weight, baseline saturation, level of dyspnea, and
lung function have greater influence on exercise cap-
acity. Handgrip strength was independently and posi-
tively related to serum total bilirubin level in both sexes
among Japanese community-dwelling persons [14]. Re-
active oxygen species and reactive nitrogen species are
generated in skeletal muscle both during rest and con-
tractile activity [15]. Intense and prolonged exercise can
result in oxidative damage to both proteins and lipids in
contracting myocytes. Low and physiological levels of re-
active oxygen species are required for normal force pro-
duction in skeletal muscle, but high levels of reactive
oxygen species promote contractile dysfunction, result-
ing in muscle weakness and fatigue [16]. Bilirubin is one
of the numerous nonenzymatic antioxidants located
within skeletal muscle fibers, and it inhibits both lipid
and protein oxidation [14]. In addition, bilirubin attenu-
ates vascular endothelial activation and dysfunction in
response to proinflammatory stress [13]. Albumin-
bound bilirubin protects human ventricular myocytes
against oxyradical damage [17].
However, the relationship of bilirubin and clinical out-
comes should be cautiously assessed in various settings
when other health statuses could confound the results.
Brown et al. showed that higher bilirubin level was asso-
ciated with lower risk of acute exacerbation of COPD
from the secondary analyses of data in the Simvastatin
for Prevention of Exacerbations in Moderate-to-Severe
COPD (STATCOPE) and the Azithromycin for Preven-
tion of Exacerbations of COPD (MACRO) studies [8].
However, we found contradicting results, as a higher
bilirubin level was associated with higher risk of exacer-
bation of COPD, especially in the GOLD III-IV group.
This result could be cautiously explained by the relation-
ship between bilirubin and right-heart function. Poelzl
et al. showed that the median total bilirubin level in-
creased with every New York Heart Association class
[18]. Moreover, Samsky et al. reported that several echo-
cardiographic indices of right-heart dysfunction were re-
lated to elevated total bilirubin levels, with increased
portal vein pulsatility index having the best predictive
value in patients with exacerbation of chronic heart fail-
ure. Abnormal liver function test results were observed
in patients with heart failure as a result of impaired per-
fusion or increased right-sided cardiac pressures [19].
COPD patients with right-sided heart failure were at
higher risk of severe exacerbations [20]. Relative pul-
monary artery enlargement (ratio of the main pulmonary
artery diameter to the aortic diameter > 1) was a signifi-
cant biomarker for predicting future exacerbation in the
COPD gene study [21]. The ratio of the main pulmonary
artery diameter to the aortic diameter was positively re-
lated with right ventricular pressure, and a high ratio
was a significant risk factor of COPD exacerbation in
Korean COPD patients [22]. In this study, the relation-
ship between serum bilirubin and exacerbation was only
significant in the GOLD III-IV group, which had more
severe airflow limitation, but the cardiac function status
in this group is not exactly known. In STATCOPE and
MACRO, COPD patients with predicted FEV1 < 80%
were enrolled, and one-third were categorized into the
GOLD II group [23, 24]. Moreover, the study duration
of STATCOPE (median = 1.74 years) and MACRO (me-
dian = 0.55 years) was shorter than that of our study
(mean = 5.4 years).
In contrast to the findings of several previous studies,
serum bilirubin level was not associated with pulmonary
function in COPD patients. Curjuric et al. studied the
association of bilirubin with lung function in the Swiss
study on Air Pollution and Lung Disease in adults
(SAPALDIA) cohort. High bilirubin levels were signifi-
cantly associated with higher FEV1/FVC and forced ex-
piratory flow at 25–75% of the pulmonary volume
(FEF25–75%) overal l[6]. Leem et al. found significant as-
sociations of serum bilirubin levels with FEV1, FVC, and
Table 5 Regression analysis for the relationship between serum bilirubin levels and mortalitya
Whole group GOLD I-II GOLD III-IV
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Univariate
Baseline bilirubin 1.31 (0.53–3.24) 0.563 0.74 (0.14–3.79) 0.715 1.50 (0.49–4.57) 0.473
Clustered analysis 0.16 (0.02–1.10) 0.062 0.14 (0.01–2.60) 0.188 0.17 (0.01–2.27) 0.180
Multipleb
Baseline bilirubin 1.60 (0.65–3.97) 0.311 1.23 (0.24–6.26) 0.805 1.36 (0.47–3.88) 0.569
Clustered analysis 0.19 (0.03–1.19) 0.076 0.21 (0.01–4.42) 0.315 0.33 (0.03–3.86) 0.377
a ‘baseline bilirubin’ is the results of regression analysis for clinical outcomes according to the baseline bilirubin levels. ‘Clustured analysis’ is the results of
regression analysis for clinical outcomes and repeated measured serum bilirubin levels
b Adjusted for age, sex, body mass index, smoking (current and former), and baseline forced expiratory volume in 1 s
GOLD Global Initiative for Chronic Obstructive Lung Disease, HR hazard ratio, CI confidence interval
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FEF25–75% in the general population, especially in never-
smokers. Moreover, serum bilirubin levels were related
to an annual decline in FEV1, FVC, and the FEV1/FVC
ratio [9]. Apperley et al. reported that bilirubin is in-
versely related to COPD disease severity and progres-
sion. Higher serum bilirubin concentration was
associated with a higher FEV1 and less annual decline in
FEV1 [7]. In the study by Apperley et al., participants
were active smokers with mild to moderate airflow limi-
tation, defined as FEV1 between 55 and 90% predicted,
and their mean FEV1 was 75% predicted. In the GOLD
I-II group of our study, the mean FEV1 was 66.7% pre-
dicted, and half of the group had FEV1 < 70% predicted
(data not shown), meaning that airflow limitation was
more severe in our study than that in the study by
Apperley et al. Milevoj Kopcinovic et al. assessed the as-
sociation of bilirubin as an oxidative stress marker with
stable COPD patients. Although the number of partici-
pants was small, the total bilirubin levels were not differ-
ent between patients with different COPD severities
[25].
The association of serum bilirubin level with mortality
is controversial, depending on the subtypes of mortality.
Its association with overall mortality in COPD has not
been reported previously in accordance with our study.
In mild COPD, bilirubin was only inversely correlated
with coronary heart disease mortality, but not with over-
all mortality [7].
Our study had several limitations. First, methodologic-
ally, the causality between serum bilirubin level and clin-
ical consequences of COPD could not be established.
Although it is currently impossible to conduct a pro-
spective study with supplementation of bilirubin to in-
vestigate the clinical effects of bilirubin in patients with
COPD, pretreatment with gavage of indirect bilirubin at-
tenuated smoking-induced pulmonary injury by sup-
pressing inflammatory cell recruitment and pro-
inflammatory cytokine secretion and increasing anti-
inflammatory cytokine levels and antioxidant superoxide
dismutase activity in a rat model of smoking-induced
emphysema [26]. Second, a smaller number of patients
were included in our study compared with previous
large-cohort studies. However, the strength of our study
is that data from repeated measurements over a long-
term period were used. We evaluated the association of
serum bilirubin levels with clinical outcomes using two
different methods: (1) analysis of the relationship be-
tween the baseline serum bilirubin level with serial data
of various clinical parameters, (2) analysis of all repeated
serum bilirubin levels with serial measurements of clin-
ical parameters using the clustered analysis method.
Third, this cohort study did not include other factors
that may affect bilirubin levels, such as previous medica-
tion, alcohol consumption, or diet. Moreover,
parameters of cardiac functions were not fully evaluated
in KOLD cohort. Therefore, our assumption of relation-
ship between heart failure and high serum bilirubin
levels in severe airflow limitation cases could not be
proved in this study. Additionally, mortality could not be
solely by the effects of acute exacerbation because death
was defined as all cause death in our study.
Conclusion
This is the first COPD cohort study to investigate the re-
lationship of repeatedly measured serum bilirubin levels
and COPD-related clinical outcomes every year. A
higher serum bilirubin level was independently associ-
ated with increased exercise capacity, a better QoL in
patients with mild-to-moderate COPD, and a higher risk
of exacerbation in those with severe-to-very severe
COPD. Bilirubin possesses potential antioxidant and
anti-inflammatory effects. However, bilirubin should be
cautiously considered as a biomarker for predicting clin-
ical consequences in various settings of COPD.
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